Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study.

MLA

Assoumou, Lambert, et al. “Safety and Tolerability of Immune Checkpoint Inhibitors in People with HIV Infection and Cancer: Insights from the National Prospective Real-World OncoVIHAC ANRS CO24 Cohort Study.” Journal for Immunotherapy of Cancer, vol. 12, no. 8, Aug. 2024. EBSCOhost, https://doi.org/10.1136/jitc-2024-009728.

APA

Assoumou, L., Baldé, R., Katlama, C., Abbar, B., Delobel, P., Allegre, T., Lavole, A., Makinson, A., Zaegel-Faucher, O., Greillier, L., Soulie, C., Veyri, M., Bertheau, M., Algarte Genin, M., Gibowski, S., Marcelin, A.-G., Bihan, K., Baron, M., Costagliola, D., … Spano, J.-P. (2024). Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study. Journal for Immunotherapy of Cancer, 12(8). https://doi.org/10.1136/jitc-2024-009728

Chicago

Assoumou, Lambert, Raghiatou Baldé, Christine Katlama, Baptiste Abbar, Pierre Delobel, Thierry Allegre, Armelle Lavole, et al. 2024. “Safety and Tolerability of Immune Checkpoint Inhibitors in People with HIV Infection and Cancer: Insights from the National Prospective Real-World OncoVIHAC ANRS CO24 Cohort Study.” Journal for Immunotherapy of Cancer 12 (8). doi:10.1136/jitc-2024-009728.